Search
Fluperolone
go.drugbank.com/drugs/DB13491ExperimentalCategories: Corticosteroids, Moderately Potent (Group II)PEV3A
go.drugbank.com/drugs/DB05144InvestigationalPEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. … The elicited antibodies are highly specific and able to inhibit the parasite’s ability to invade liver tissue _in vitro_.
Typhoid Vaccine Live
go.drugbank.com/drugs/DB11050ApprovedInvestigationalThe vaccine prevents the development of typhoid fever, an acute, febrile enteric disease caused by *Salmonella typhi* by inducing a local immune response in the intestinal tract. … Salmonella typhi Ty21a live antigen is a live attenuated vaccine for oral administration only. It contains the attenuated strain *Salmonella typhi* Ty21a.
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.
99mTc-glucarate
go.drugbank.com/drugs/DB05810Investigational99mTc-glucarate(GLA) is an agent for non-invasive detection of breast tumours.
Avasopasem manganese
go.drugbank.com/drugs/DB16354Investigational[L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19. … Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.
HLX70
go.drugbank.com/drugs/DB16509Investigationalin healthy adult volunteers. … The condition targeted by HLX70 in this study is COVID-19.
Besigomsin
go.drugbank.com/drugs/DB20894ExperimentalBesigomsin is a small molecule drug. Besigomsin has a monoisotopic molecular weight of 416.18 Da.
Categories: Compounds used in a research, industrial, or household settingGLB-001
go.drugbank.com/drugs/DB32795InvestigationalGLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).[L56124, L56125, L56126]